An observational study in Gastric / Gastroesophageal Junction Adenocarcinoma, Mismatch Repair Deficient or MSI-High Solid Tumors and Lymph Node Metastasis, sponsored by Shanghai Zhongshan Hospital. Not yet recruiting. Open to participants aged 18 Years to 95 Years. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Shanghai Zhongshan Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Lymph node metastasis (LNM) is a key factor influencing treatment decisions and prognosis in patients with gastric cancer. Lymphatic invasion (LI) is an important pathological predictor of LNM and a core component of the eCURA risk scoring system after endoscopic submucosal dissection (ESD) for early gastric cancer. However, whether LI has the same predictive value for LNM across different mismatch repair (MMR) statuses remains unclear. Compared with proficient mismatch repair (pMMR) gastric cancer, deficient mismatch repair (dMMR) gastric cancer has distinct molecular pathological features and an immune-enriched tumor microenvironment. In early gastric cancer, if LI is associated with a lower LNM risk in dMMR tumors than in pMMR tumors, existing LI-based eCURA risk assessment may overestimate LNM risk in patients with dMMR early gastric cancer and consequently affect decisions regarding additional surgery after ESD.
Therefore, this study aims to systematically evaluate the association between MMR status, LI, and LNM using multi-center cohorts of patients with GC who underwent upfront gastrectomy or additional gastrectomy following ESD, and to explore the potential clinical value of incorporating MMR status into eCURA-based risk stratification for early GC. Furthermore, an independent colorectal cancer surgical cohort will be included to investigate whether these associations are consistent across different gastrointestinal malignancies.
60 studies on the registry are indexed under Turcot syndrome; 29 are open to participants now.
This study's planned enrollment of 5,000 is above the median of 671 across 13 observational studies indexed under Turcot syndrome.
Browse Turcot syndrome studies →Shanghai Zhongshan Hospital is the lead sponsor of 654 studies on the registry; 293 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Oct 27, 2026. See what changed
This multicenter, retrospective observational cohort study will include patients with pathologically confirmed gastric or gastroesophageal junction adenocarcinoma or colorectal adenocarcinoma treated at Zhongshan Hospital, Fudan University, and five participating centers in China.
Patients treated between January 2018 and April 2026 will be retrospectively identified from electronic medical records, surgical records, and pathology databases. The study population comprises three cohorts:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Gastric cancer upfront surgery cohort
Gastric cancer ESD cohort
Colorectal cancer upfront surgery cohort
Exclusion Criteria:
Gastric cancer upfront surgery cohort
Gastric cancer ESD cohort
Colorectal cancer upfront surgery cohort
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with gastric cancer classified as deficient mismatch repair (dMMR) based on routine pathological testing.
Other: Mismatch repair (MMR) status · Other: Lymphatic invasion status
Patients with gastric cancer classified as proficient mismatch repair (pMMR) based on routine pathological assessment.
Other: Mismatch repair (MMR) status · Other: Lymphatic invasion status
Patients with pathologically confirmed colorectal adenocarcinoma classified as deficient mismatch repair (dMMR) based on routine immunohistochemical assessment of MLH1, PMS2, MSH2, and MSH6.
Other: Mismatch repair (MMR) status · Other: Lymphatic invasion status
Patients with pathologically confirmed colorectal adenocarcinoma classified as proficient mismatch repair (pMMR) based on routine immunohistochemical assessment of MLH1, PMS2, MSH2, and MSH6.
Other: Mismatch repair (MMR) status · Other: Lymphatic invasion status
Mismatch repair (MMR) status was assessed as part of routine pathological evaluation. Patients were classified as deficient mismatch repair (dMMR) or proficient mismatch repair (pMMR) according to immunohistochemical expression of MLH1, PMS2, MSH2, and MSH6.
Lymphatic invasion status was determined from routine pathological reports and classified as LI-positive or LI-negative.
Lymph Node Metastasis Rate Among LI-Positive Gastric Cancer Patients
LI positivity is defined as lymphatic invasion explicitly documented in the pathological report or tumor emboli within lymphatic vessels confirmed by D2-40 immunohistochemistry. LNM is defined as regional lymph node metastasis confirmed by postoperative pathological examination. The LNM rate among LI-positive patients is calculated as the number of patients with LNM divided by the total number of LI-positive patients in the corresponding group.
Time frame: At postoperative pathological assessment, approximately 14 days after upfront surgery
LI Positivity Rate According to MMR Status
This outcome evaluates differences in LI positivity rate between patients with dMMR and pMMR gastric cancer. LI positivity rate is calculated as the number of LI-positive patients divided by the total number of patients in each MMR group.
Time frame: At postoperative pathological assessment, approximately 14 days after upfront surgery
Overall LNM Rate According to MMR Status
This outcome evaluates differences in overall LNM rate between patients with dMMR and pMMR gastric cancer. Overall LNM rate is calculated as the number of patients with pathologically confirmed LNM divided by the total number of patients in each MMR group.
Time frame: At postoperative pathological assessment, approximately 14 days after upfront surgery
eCURA Risk Stratification and LI Contribution in the Gastric Cancer ESD Cohort
This outcome evaluates differences in eCURA classification, eCURA risk score distribution, and the contribution of LI to the risk score between dMMR and pMMR patients in the gastric cancer ESD cohort. LI contribution is assessed based on its role in eCURA-C2 classification and/or its component score contribution within the eCURA risk scoring system.
Time frame: At pathological assessment of the ESD specimen, approximately 14 days after ESD
LNM Rate Among LI-Positive Patients in the cohort undergoing additional gastrectomy after ESD
This outcome evaluates differences in LNM risk between LI-positive dMMR and pMMR patients with early gastric cancer who underwent additional surgery after ESD. LNM is defined as regional lymph node metastasis confirmed by pathological examination of the additional surgical specimen. LNM rate is calculated as the number of patients with LNM divided by the total number of LI-positive patients in each MMR group.
Time frame: At postoperative pathological assessment, approximately 14 days after additional surgery
LNM Rate Among LI-Positive Colorectal Cancer Patients According to MMR Status
This outcome compares the rate of pathologically confirmed LNM between LI-positive dMMR and pMMR colorectal cancer patients. LNM rate is calculated as the number of patients with LNM divided by the total number of LI-positive patients in each MMR group. Exploratory subgroup analyses will be performed according to pathological T stage.
Time frame: At postoperative pathological assessment, approximately 14 days after upfront surgery.
LI Positivity Rate According to MMR Status in Colorectal Cancer
This outcome compares the proportion of LI-positive patients between dMMR and pMMR colorectal cancer groups. LI positivity rate is calculated as the number of LI-positive patients divided by the total number of patients in each MMR group.
Time frame: At postoperative pathological assessment, approximately 14 days after upfront surgery.
Overall LNM Rate According to MMR Status in Colorectal Cancer
This outcome compares the overall rate of pathologically confirmed LNM between dMMR and pMMR colorectal cancer patients. LNM rate is calculated as the number of patients with LNM divided by the total number of patients in each MMR group.
Time frame: At postoperative pathological assessment, approximately 14 days after upfront surgery.
No study locations are listed for this record.
Plan to share: No — Individual participant data will not be publicly shared due to patient privacy concerns and institutional data protection regulations. De-identified aggregate data may be made available from the corresponding author upon reasonable request and with appropriate institutional approval.
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Jan 2027, 2 months later.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: start Jul 2026 → Nov 2026 and primary completion Nov 2026 → Jan 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.